You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on cancer immunotherapy.
With RNA sequencing and other data, researchers gauged neoantigen formation, immunoediting, and clonal evolution in non-small cell lung cancers.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
In Science this week: a pair of papers finds cytosine base editors can generate off-target mutations, and more.
Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
In Nature this week: genomic factors that influence glioblastoma response to anti-PD-1 therapy, sequencing test for infectious disease, and more.
Researchers identified PTEN mutations, MAP kinase pathway alterations, and other features linked to anti-PD-1 response in individuals with the brain cancer.
In Science this week: discussion of combining immunotherapies with targeted treatments, and more.
The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.
The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.
Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.
Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.
Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.
In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.